NCT02779283 - Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 13, 2016

Primary Completion Date

April 19, 2018

Study Completion Date

September 20, 2018

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Cytarabine

Given IV

DRUG

Dasatinib

Given PO

DRUG

Dexamethasone

Given PO

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Idarubicin

Given IV

DRUG

Idelalisib

Given PO

DEVICE

In Vitro Kinase Inhibitor Assay

Correlative studies

DRUG

Leucovorin Calcium

Given IV

DRUG

Methotrexate

Given IV

DRUG

Methylprednisolone Sodium Succinate

Given IV

DRUG

Ponatinib Hydrochloride

Given PO

BIOLOGICAL

Rituximab

Given IV

DRUG

Ruxolitinib Phosphate

Given PO

DRUG

Sorafenib Tosylate

Given PO

DRUG

Sunitinib Malate

Given PO

DRUG

Vincristine Sulfate

Given IV

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

OHSU Knight Cancer Institute

OTHER